{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'discontinue study treatment and continue', 'liver injury, or hypersensitivity, on', 'participant in the study for any protocol', 'the AE report form', 'specified follow up assessments', 'Record use of concomitant', 'medications on the concomitant', 'MONITORING:', 'medications report form including', 'acetaminophen, herbal remedies,', 'For bilirubin or INR criteria:', 'other over the counter medications.', 'Repeat liver chemistries (include ALT,', 'Record alcohol use on the liver', 'AST, alkaline phosphatase, bilirubin) and', 'event alcohol intake case report', 'perform liver event follow up assessments', 'form (CRF) page', 'within 24 hrs', 'Monitor participants twice weekly until', 'liver chemistries resolve, stabilize or return', 'to within baseline', 'For bilirubin or INR criteria:', 'A specialist or hepatology consultation is', 'Anti-nuclear antibody, anti-smooth', 'recommended', 'muscle antibody, Type 1 anti-liver', 'kidney microsomal antibodies, and', 'For All other criteria:', 'quantitative total immunoglobulin', 'Repeat liver chemistries (include ALT,', 'G (IgG) or gamma globulins.', 'AST, alkaline phosphatase, bilirubin) and', 'Serum acetaminophen adduct high', 'perform liver event follow up assessments', 'performance liquid chromatography', 'within 24-72 hrs', '(HPLC) assay (quantifies potential', 'Monitor participants weekly until liver', 'acetaminophen contribution to liver', 'chemistries resolve, stabilize or return to', 'injury in participants with definite', 'within baseline', 'or likely acetaminophen use in the', 'preceding week [James, 2009].', 'Liver imaging (ultrasound,', 'magnetic resonance, or', 'computerised tomography) and /or', 'liver biopsy to evaluate liver', 'disease complete Liver Imaging', 'and/or Liver Biopsy CRF pages.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 2xULN..', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM);', 'Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable,', 'obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody', '76']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. PK sample may not be required for participants known to be receiving placebo or non-GSK comparator', 'treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the', \"participant's best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot\", 'be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and', 'shipping are in the SRM.', 'Phase II liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'Notify the GSK medical monitor within 24 hours of', 'ALT >3xULN and <5xULN and bilirubin', 'learning of the abnormality to discuss participant', '<2xULN, without symptoms believed to', 'safety.', 'be related to liver injury or', 'Participant can continue study treatment', 'hypersensitivity, and who can be', 'monitored weekly for 4 weeks', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilise or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', 'Reference', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', '77']\n\n###\n\n", "completion": "END"}